Compare FOXF & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FOXF | IMMX |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 800.6M | 716.2M |
| IPO Year | 2013 | 2021 |
| Metric | FOXF | IMMX |
|---|---|---|
| Price | $19.94 | $12.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $30.25 | $19.20 |
| AVG Volume (30 Days) | 378.3K | ★ 1.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,467,321,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.27 | N/A |
| 52 Week Low | $13.08 | $1.94 |
| 52 Week High | $28.76 | $15.10 |
| Indicator | FOXF | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 51.84 |
| Support Level | $15.62 | $7.96 |
| Resistance Level | $19.75 | $15.10 |
| Average True Range (ATR) | 0.74 | 0.81 |
| MACD | -0.25 | -0.25 |
| Stochastic Oscillator | 19.34 | 24.76 |
Fox Factory Holding Corp is a designer, manufacturer, and marketer of performance-defining products and systems used predominantly on bikes, Side-by-Sides, on-road vehicles with and without off-road capabilities, off-road vehicles and trucks, ATVs, snowmobiles, specialty vehicles and applications, motorcycles, and commercial trucks. Its business operates under the FOX, FOX RACING SHOX, and RACE FACE brands. Geographically, it derives a majority of revenue from North America and also has a presence in Asia, Europe, and the Rest of the World. The company operates in three segments: Powered Vehicles Group, Aftermarket Applications Group, and Specialty Sports Group, of which it derives maximum revenue from Specialty Sports Group segment.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.